A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

Inclusion Criteria: * Histopathologically or cytologically confirmed advanced HCC * No previous systematic treatment for HCC * Have at least one measurable lesion (in accordance with RECIST v1.1) * BCLC stage B or C, and not suitable for surgical or local therapy, or has progressed following surgical and/or local therapy * ECOG-PS score 0 or 1 * Child-Pugh Class: Grade A * Life Expectancy of at least 12 weeks * Subjects with HBV infection: HBV DNA\<500 IU/ml or \< 2500 copy/mL, and have received anti-HBV therapy for at least 14 days prior to enrollment in the study * Subjects with HCV-RNA(+) must receive antiviral therapy * Adequate organ function Exclusion Criteria: * Known hepatocholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma and lamellar cell carcinoma; other active malignant tumor except HCC within 5 years or simultaneously * Moderate-to-severe ascites with clinical symptoms * History of gastrointestinal hemorrhage within 6 months prior to the start of study treatment or clear tendency of gastrointestinal hemorrhage * Abdominal fistula, gastrointestinal perforation or intraperitoneal abscess within 6 months prior to the start of study treatment * Known genetic or acquired hemorrhage or thrombotic tendency * Thrombosis or thromboembolic event within 6 months prior to the start of study treatment * Cardiac clinical symptom or disease that is not well controlled * Hypertension that can not be well controlled through antihypertensive drugs * Factors to affect oral administration * History of hepatic encephalopathy * Previous or current presence of metastasis to central nervous system * HIV infection * Combined hepatitis B and hepatitis C co-infection * Be ready for or previously received organ or allogenic bone marrow transplantation * Interstitial lung disease that is symptomatic or may interfere with the detection and management of suspected drug-related pulmonary toxicity * Active known, or suspected autoimmune disease * Subjects with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of first administration of study treatment * Use of potent CYP3A4 inducers or inhibitors within 2 weeks prior to the signature of ICF * Known history of serious allergy to any monoclonal antibody or targeted anti-angiogenic drug * Severe infection within 4 weeks prior to the start of study treatment * Palliative radiotherapy for non-target lesions to control symptoms is allowed, but it must be completed at least 2 weeks prior to the start of study treatment * Treatment of other investigational product(s) within 28 days prior to the start of study treatment